Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth
Open Access
- 15 June 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (12), 3993-4005
- https://doi.org/10.1158/1078-0432.ccr-10-2243
Abstract
Purpose: Metformin is a widely used antidiabetic drug whose anticancer effects, mediated by the activation of AMP-activated protein kinase (AMPK) and reduction of mTOR signaling, have become noteworthy. Chemotherapy produces genotoxic stress and induces p53 activity, which can cross-talk with AMPK/mTOR pathway. Herein, we investigate whether the combination of metformin and paclitaxel has an effect in cancer cell lines.Other Versions
This publication has 48 references indexed in Scilit:
- Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy stateJCI Insight, 2010
- Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong RemissionCancer Research, 2009
- Antidiabetic Therapies Affect Risk of Pancreatic CancerGastroenterology, 2009
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- New Users of Metformin Are at Low Risk of Incident CancerDiabetes Care, 2009
- Targeting the mTOR Signaling Network for Cancer TherapyJournal of Clinical Oncology, 2009
- Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes MellitusJAMA, 2008
- p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR SignalingCell, 2008
- Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient miceBiochemical Journal, 2008
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006